The U.S. Food and Drug Administration (FDA) has agreed to allow Fibrocell Science to begin clinical trials testing its lead candidate FCX-013 for the treatment of moderate to severe localized scleroderma. This news comes on the heels of an investigational new drug (IND) application that was filed…
News
It takes more than three years for half of Britons with rheumatic diseases like scleroderma, lupus and vasculitis to obtain a correct diagnosis, according to a Rare Autoimmune Rheumatic Diseases Alliance report. This means a major delay in obtaining the treatment they need, according to the report, titled “Reduce, Improve, Empower.” It…
Retrophin and the U.S. subsidiary of Britain’s Horizon Pharma will each donate $3 million over a six-year period to the Rare Disease Institute (RDI) at Children’s National Health System in Washington, D.C., helping it to strengthen care available and expand as a “center of excellence” for rare…
Implanting some of scleroderma patients’ fat cells in their fingers significantly improved their hand function and overall disability, a clinical trial showed. The STAR trial (NCT02396238) dealt with Cytori Therapeutics’ Habeo cell therapy. It involved placing fat — or adipose — cells under the skin of each finger. Cytori presented…
In recognition of Rare Disease Day 2018, Bionews Services — which publishes this website — will attend and report on three relevant conferences in the U.S. dealing with policies and programs of importance to patients and their families. The three are among 50 events in 32 states…
Boehringer Ingelheim and the Scleroderma Foundation have started a global initiative to raise awareness of scleroderma and support those with the life-threatening disease. In conjunction with the initiative, which is dubbed More Than Scleroderma: The Inside Story, they created a website that will feature the latest scientific knowledge and news on…
A rock-painting contest in Las Vegas. A fashion show in New York. A 7,000-meter race around the Washington Monument that’ll coincide with a similar #Racefor7 event in Bengaluru and Mumbai, India. From Athens to Atlanta, from San Diego to Sydney, people across the globe will mark World Rare Disease…
The European Medicines Agency has granted orphan drug designation to Emerald Health Pharmaceuticals’ lead cannabis-based product for treating systemic scleroderma. EHP-101 is derived from cannabidiol, a chemical found in the cannabis plant. The therapy activates the cell-surface receptors PPARγ and CB2, which in turn activate cell signaling pathways that can…
The National Institutes of Health’s (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) recently awarded five new Core Centers for Clinical Research (CCCR), one of them with a particular focus on scleroderma. The goal of the CCCRs is to develop and apply methods that…
David Curtis Glebe, a retired 64-year-old public prosecutor now living in Millsboro, Delaware, knows he’s lucky to be alive. In mid-2013, while in Arizona, Glebe was diagnosed with pancreatic neuroendocrine cancer (PNET) — the same disease that killed Apple’s founder and CEO Steve Jobs. After three years of progress…
Recent Posts
- Antibody levels may help reflect quality of life in people with scleroderma
- Certain antibodies tied to poorer outcomes in systemic sclerosis
- Dexamethasone reduces inflammation, scarring in SSc mouse model: Study
- Survival improves for SSc-PAH patients on combination therapy
- Combination drug therapy boosts lung, skin health in SSc patients
- On choosing medicine’s side effects over scleroderma progression
- Telerehabilitation improves hand mobility in scleroderma women
- Molecular pathway ID’d as key driver of scarring in scleroderma
- Limited hand function disrupts daily life for people living with SSc
- Coping with loss is part of living with scleroderma